HK Stock Market Move | ASCENTAGE (06855) Rises Over 5%; Multiple Clinical Advances to Be Presented at the ASH Annual Meeting, APG-5918 Receives Oral Presentation Upon First Disclosure

ASCENTAGE (06855) rose over 5%. As of press time, it was up 5.08% at HK$29.78, with a turnover of HK$14.6293 million. On the news front, ASCENTAGE announced that multiple clinical and preclinical research advances have been selected for presentation at the 68th American Society of Hematology (ASH) Annual Meeting, covering four assets: olverembatinib (brand name: Nailike), China's first approved third-generation BCR-ABL inhibitor; lisaftoclax (brand name: Lishengtuo), China's first approved domestically developed Bcl-2 inhibitor; APG-5918, a PRC2/EED inhibitor; and APG-3288, a BTK degrader. Together they fully demonstrate the company's deep footprint and global innovation strength in the hematologic oncology field. Notably, APG-5918 received an oral presentation upon its first disclosure of clinical data. At this ASH Annual Meeting, APG-5918 will present, in an oral presentation, the first disclosure of its efficacy and safety clinical data for the treatment of relapsed/refractory T-cell lymphoma (R/R TCL). R/R TCL is a highly heterogeneous disease; some patients are resistant to existing chemotherapy and targeted therapies, clinical treatment options are limited, and there is a significant unmet medical need. As a novel EED inhibitor, APG-5918 has demonstrated encouraging antitumor activity and manageable safety in early clinical studies, and is expected to provide a new epigenetic-targeted treatment option for these refractory TCL patients.